Home  |  Contact

UniProtKB/Swiss-Prot Q9BXJ9: Variant p.Lys450Glu

N-alpha-acetyltransferase 15, NatA auxiliary subunit
Gene: NAA15
Chromosomal location: 4q31.1
Variant information

Variant position:  450
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Lysine (K) to Glutamate (E) at position 450 (K450E, p.Lys450Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (K) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Mental retardation, autosomal dominant 50 (MRD50) [MIM:617787]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. {ECO:0000269|PubMed:28191889}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In MRD50; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  450
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  866
The length of the canonical sequence.

Location on the sequence:   WMDEAQALDTADRFINSKCA  K YMLKANLIKEAEEMCSKFTR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         WMDEAQALDTADRFINSKCAKYMLKANLIKEAEEMCSKFTR

Mouse                         WMDEAQALDTADRFINSKCAKYVLKANLIKEAEEMCSKFTR

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 866 N-alpha-acetyltransferase 15, NatA auxiliary subunit
Helix 442 – 454


Literature citations

Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases.
Stessman H.A.; Xiong B.; Coe B.P.; Wang T.; Hoekzema K.; Fenckova M.; Kvarnung M.; Gerdts J.; Trinh S.; Cosemans N.; Vives L.; Lin J.; Turner T.N.; Santen G.; Ruivenkamp C.; Kriek M.; van Haeringen A.; Aten E.; Friend K.; Liebelt J.; Barnett C.; Haan E.; Shaw M.; Gecz J.; Anderlid B.M.; Nordgren A.; Lindstrand A.; Schwartz C.; Kooy R.F.; Vandeweyer G.; Helsmoortel C.; Romano C.; Alberti A.; Vinci M.; Avola E.; Giusto S.; Courchesne E.; Pramparo T.; Pierce K.; Nalabolu S.; Amaral D.G.; Scheffer I.E.; Delatycki M.B.; Lockhart P.J.; Hormozdiari F.; Harich B.; Castells-Nobau A.; Xia K.; Peeters H.; Nordenskjoeld M.; Schenck A.; Bernier R.A.; Eichler E.E.;
Nat. Genet. 49:515-526(2017)
Cited for: INVOLVEMENT IN MRD50; VARIANTS MRD50 52-LYS--ILE-866 DEL; ASN-112; 290-GLY--ILE-866 DEL; GLU-450; VAL-475; 565-TYR--ILE-866 DEL; 696-LYS--ILE-866 DEL; 782-ARG--ILE-866 DEL AND 797-ARG--ILE-866 DEL;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.